BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/12/2022 6:36:34 AM | Browse: 410 | Download: 1229
 |
Received |
|
2022-08-11 03:50 |
|
Peer-Review Started |
|
2022-08-11 03:53 |
|
First Decision by Editorial Office Director |
|
2022-10-05 07:30 |
|
Return for Revision |
|
2022-10-06 01:20 |
|
Revised |
|
2022-10-17 04:13 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-11-10 03:33 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-11-16 17:32 |
|
Articles in Press |
|
2022-11-16 17:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-12-05 03:40 |
|
Publish the Manuscript Online |
|
2022-12-12 06:36 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Inhibition of bromodomain-containing protein 4 enhances the migration of esophageal squamous cell carcinoma cells by inducing cell autophagy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wen-Qian Yang, Rui Liang, Man-Qi Gao, Yu-Zhen Liu, Bo Qi and Bao-Sheng Zhao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Health Commission of Henan Province of China |
SBGJ202102188 |
| Key Project of Science and Technology of Xinxiang |
GG2020027 |
|
| Corresponding Author |
Bao-Sheng Zhao, BMed, Chief Physician, Professor, Department of Thoracic Surgery, The First Affiliated Hospital of Xinxiang Medical University, No. 88 Jiankang Road, Weihui 453100, Henan Province, China. drbszhao@xxmu.edu.cn |
| Key Words |
JQ1; Bromodomain-containing protein 4; Cell migration; Cell autophagy; Epithelial-mesenchymal transition; Esophageal squamous cell carcinoma |
| Core Tip |
It has been demonstrated that bromodomain-containing protein 4 (BRD4) as a transcriptional regulator promotes tumor development. Thus, targeting of BRD4 has recently emerged as a promising anti-cancer therapeutic strategy. We present here that BRD4 inhibition suppresses esophageal squamous cell carcinoma (ESCC) cell proliferation, but promotes ESCC cell migration by induction of autophagy, which further facilities epithelial-mesenchymal transition process. Our study implies that the migration-promoting effect should be carefully considered when clinical targeting BRD4 as anti-cancer approach and combination with autophagy inhibitor might be a new therapeutic strategy to avoid the deleterious role of BRD4-targeted strategies. |
| Publish Date |
2022-12-12 06:36 |
| Citation |
Yang WQ, Liang R, Gao MQ, Liu YZ, Qi B, Zhao BS. Inhibition of bromodomain-containing protein 4 enhances the migration of esophageal squamous cell carcinoma cells by inducing cell autophagy. World J Gastrointest Oncol 2022; 14(12): 2340-2352 |
| URL |
https://www.wjgnet.com/1948-5204/full/v14/i12/2340.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v14.i12.2340 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
